Abbott Laboratories (SWX:ABT)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
102.00
-2.00 (-1.92%)
Jul 31, 2025, 11:52 PM CET
-1.92%
Market Cap178.38B
Revenue (ttm)34.96B
Net Income (ttm)11.10B
Shares Outn/a
EPS (ttm)6.35
PE Ratio16.06
Forward PE23.16
Dividend1.96 (1.93%)
Ex-Dividend DateOct 15, 2025
Volume35
Average Volume2
Open102.00
Previous Close104.00
Day's Range102.00 - 102.00
52-Week Range92.00 - 106.00
Beta0.68
RSI1.21
Earnings DateOct 15, 2025

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]

Sector Healthcare
Founded 1888
Employees 114,000
Stock Exchange SIX Swiss Exchange
Ticker Symbol ABT
Full Company Profile

Financial Performance

In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.

Financial numbers in USD Financial Statements

News

Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports

Walmart will become the first U.S. retailer to sell an over-the-counter continuous glucose monitor in physical stores, as Abbott Laboratories' Lingo rolls out to more than 3,500 locations and online, ...

11 hours ago - Reuters

Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming

The market has overreacted to ABT's lowered FY2025 organic sales growth/narrowed adj. EPS, since the management continues to deliver robust numbers while building upon FY2024 outperformance. Much of i...

3 days ago - Seeking Alpha

Peter Lynch Detailed Fundamental Analysis - ABT

Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of ...

4 days ago - Nasdaq

S&P 500 Analyst Moves: ABT

The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #85 analyst pick, moving up by 1 spot. This ra...

4 days ago - Nasdaq

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength

Abbott Laboratories (NYSE: ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance . The company reported third-quarter sales of $11.37 billion, slightly mis...

5 days ago - Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Abbott Laboratories (NYSE: ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday. The company reported third-quarter sales of $11.37 billion, slightly missing ...

5 days ago - Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.

5 days ago - Benzinga

Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $146 | ABT Stock News

Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $146 | ABT Stock News

5 days ago - GuruFocus

Salesforce mit neuen Plänen, TSMC stark, Morgan Stanley toppt Erwartungen • news

FlatexDeGiro, Sartorius, Abbott Laboratories, Bank of America, Morgan Stanley, United Airlines, Apple, Nvidia, Arm, Hims & Hers, Salesforce, Taiwan Semi.

5 days ago - Onvista

Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical ...

Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical Devices Lead the Way

6 days ago - GuruFocus

Abbott Laboratories (ABT) Sees Robust Growth in Q3 2025

Abbott Laboratories (ABT) Sees Robust Growth in Q3 2025

6 days ago - GuruFocus

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.06% to 46,299.96 while the NASDAQ climbed 0.52% to 22,639....

6 days ago - Benzinga

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

Abbott Laboratories (NYSE:ABT) stock fell around 2.6% on Wednesday after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.

6 days ago - Benzinga

Q3 2025 Abbott Laboratories Earnings Call Transcript

Q3 2025 Abbott Laboratories Earnings Call Transcript

6 days ago - GuruFocus

Abbott Laboratories' Q3 2025 Results: Steady Performance with Limited Upside

Abbott Laboratories' Q3 2025 Results: Steady Performance with Limited Upside

6 days ago - GuruFocus

ABT Makes Notable Cross Below Critical Moving Average

In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $130.01, changing hands as low as $127.88 per share. Abbott Laboratories shares are c...

6 days ago - Nasdaq

Abbott Laboratories (ABT) Faces Revenue Shortfall Despite Earnings Alignment

Abbott Laboratories (ABT) Faces Revenue Shortfall Despite Earnings Alignment

6 days ago - GuruFocus

Abbott Laboratories (ABT) Stock Dips After Q3 2025 Miss

Abbott Laboratories (ABT) Stock Dips After Q3 2025 Miss

6 days ago - GuruFocus

Abbott Laboratories (ABT) Anticipates Earnings Surge

Abbott Laboratories (ABT) Anticipates Earnings Surge

6 days ago - GuruFocus

Abbott Tightens Annual Sales Forecast As Q3 Sales Miss Expectations

Abbott Laboratories (NYSE: ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance. The company reported third-quarter sales of $11.37 billion, s...

6 days ago - Benzinga

Abbott Laboratories (ABT) Reports Mixed Q3 Results

Abbott Laboratories (ABT) Reports Mixed Q3 Results

6 days ago - GuruFocus

Abbott Laboratories Q3 Earnings: Adjusted EPS of $1.30 Beats Estimates, Revenue at $11. ...

Abbott Laboratories Q3 Earnings: Adjusted EPS of $1.30 Beats Estimates, Revenue at $11.369 Billion Slightly Misses Expectations

6 days ago - GuruFocus